This disclosure relates to a composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid (UDCA). More particularly, this disclosure relates to an excellent pharmaceutical composition for the prevention or the treatment of visual impairments such as macular degeneration, glaucoma and diabetic retinopathy which can be formulated for an oral administration, an intravitreal injection, or an eye drop administration by aqueous solubilized ursodeoxycholic acid.